For example, Vemurafenib (BRAF V600E inhibitor) and Ipilimumab (anti-CTLA4) were recently approved by the U.S. FDA and agents directed against the MAP kinase pathway (anti-MEK, anti-ERK, other anti-BRAF) are under development for targeted therapy in cases of advanced metastatic melanoma [79]. The gene discussed is BRAF; the disease is metastatic melanoma.